Left Menu
Development News Edition

EU eyes tougher measures against foreign industrial espionage

The European Commission is planning tougher measures to prevent foreign countries acquiring European firms' intellectual property, a move that could strain relations with China, the United States and other trade partners.

Reuters | Brussels | Updated: 25-11-2020 17:57 IST | Created: 25-11-2020 17:00 IST
EU eyes tougher measures against foreign industrial espionage
Representative image

The European Commission is planning tougher measures to prevent foreign countries acquiring European firms' intellectual property, a move that could strain relations with China, the United States and other trade partners. Most of the 27-nation bloc's exports are of goods produced by industries which rely on patents, such as cars and other high-tech products. But outside the EU, there is insufficient intellectual property (IP) protection for EU firms, the European Union executive said.

"Our businesses still face major challenges when operating in third countries, including uneven protection standards, or regulatory frameworks forcing transfer of IP as a de facto pre-condition for accessing local markets," the Commission said in a document published on Wednesday, hinting at practices that are common in China. In an action plan which outlines possible future moves, the Commission said it would take stronger measures to prevent foreign nations appropriating EU firms' intellectual property through research projects, takeovers or outright espionage.

The Commission is developing new rules to regulate cooperation with foreign research labs, it said. "It will also take a critical look at foreign takeovers targeting critical IP assets," the document added.

In March, the EU in effect blocked an attempt by the United States to gain access to patents developed by CureVac, a German biotech firm that is pioneering a new technology to produce vaccines. CureVac's messenger RNA (mRNA) COVID-19 vaccine candidate, which uses the same technology as shots being developed by U.S. firms Pfizer and Moderna, is one of those booked by the EU and in the shortlist of a global procurement scheme co-led by the World Health Organization for the fight against the new coronavirus.

Brussels also plans to step up its fight against counterfeiting and simplify rules on patents to boost the ability of smaller firms to protect their intellectual property.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

China: A savior for emerging markets or a poison pill?

... ...

Future of Urban Planning: Artificial Intelligence guiding the way

Advances in emerging technologies like Artificial Intelligence and Machine Learning can help us understand our cities better and derive useful insights from real-time data collected through automated models....

Videos

Latest News

U.S. Senate panel backs confirmation of Blinken to be top U.S. diplomat

The U.S. Senate Foreign Relations Committee on Monday approved the nomination of veteran diplomat Antony Blinken to serve as secretary of state, clearing the way for his consideration by the full Senate as soon as this week.The committee vo...

Soccer-Reaction to Chelsea's sacking of manager Frank Lampard

Reaction to the sacking of Chelsea manager Frank Lampard on MondayCHELSEA OWNER ROMAN ABRAMOVICH This was a very difficult decision for the Club, not least because I have an excellent personal relationship with Frank and I have the utmost r...

Biden extends Europe, Brazil travel restrictions, adds South Africa

U.S. President Joe Biden signed an order on Monday barring most non-U.S. citizens who have recently been in South Africa from entering the United States, effective Saturday. Bidens order also reimposes an entry ban, set to expire on Tuesday...

Judge orders Merck documents on anti-baldness drug Propecia unsealed

A U.S. judge granted a Reuters request to unseal Merck Co documents produced in lawsuits related to its anti-baldness treatment Propecia, finding that the publics right to access outweighed the drug makers arguments for keeping the informa...

Give Feedback